Aguilar RB - Search Results

1

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.

Davidson JA, Lajara R, Aguilar RB, Mattheus M, Woerle HJ, von Eynatten M. Davidson JA, et al. Among authors: aguilar rb. BMJ Open Diabetes Res Care. 2014 Apr 16;2(1):e000020. doi: 10.1136/bmjdrc-2014-000020. eCollection 2014. BMJ Open Diabetes Res Care. 2014. PMID: 25452864 Free PMC article.

2

Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.

Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M. Lajara R, et al. Clin Ther. 2014 Nov 1;36(11):1595-605. doi: 10.1016/j.clinthera.2014.07.020. Epub 2014 Sep 16. Clin Ther. 2014. PMID: 25236917 Free article.

3

Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.

Davidson JA, Aguilar R, Lavalle González FJ, Trujillo A, Alba M, Vijapurkar U, Meininger G. Davidson JA, et al. Ethn Dis. 2016 Apr 21;26(2):221-8. doi: 10.18865/ed.26.2.221. Ethn Dis. 2016. PMID: 27103773 Free PMC article.

4

Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success.

Aguilar RB. Aguilar RB. Clin Ther. 2011 Apr;33(4):408-24. doi: 10.1016/j.clinthera.2011.04.008. Clin Ther. 2011. PMID: 21635988 Review.

5

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.

Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB. Schwartz SS, et al. Among authors: aguilar rb. Diabetes Care. 2016 Feb;39(2):179-86. doi: 10.2337/dc15-1585. Diabetes Care. 2016. PMID: 26798148 Free PMC article.

6

Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.

Thayer S, Chow W, Korrer S, Aguilar R. Thayer S, et al. Curr Med Res Opin. 2016 Jun;32(6):1087-96. doi: 10.1185/03007995.2016.1159954. Epub 2016 Mar 16. Curr Med Res Opin. 2016. PMID: 26938635

7

Managing type 2 diabetes in men.

Aguilar R. Aguilar R. J Fam Pract. 2012 Jun;61(6 Suppl):S16-21. J Fam Pract. 2012. PMID: 22670243 Review.

8

Response to Comment on Schwartz et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. Diabetes Care 2016;39:179-186.

Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB. Schwartz SS, et al. Among authors: aguilar rb. Diabetes Care. 2016 Aug;39(8):e129-30. doi: 10.2337/dci16-0011. Diabetes Care. 2016. PMID: 27457644 No abstract available.

9

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

Shaefer CF Jr, Kushner P, Aguilar R. Shaefer CF Jr, et al. Postgrad Med. 2015;127(8):818-26. doi: 10.1080/00325481.2015.1090295. Epub 2015 Sep 15. Postgrad Med. 2015. PMID: 26371721 Review.

10

HbA_1c Outcomes in Patients Treated With Canagliflozin Versus Sitagliptin in US Health Plans.

Thayer S, Aguilar R, Korrer S, Chow W. Thayer S, et al. Clin Ther. 2017 Oct;39(10):2061-2072. doi: 10.1016/j.clinthera.2017.08.019. Epub 2017 Sep 22. Clin Ther. 2017. PMID: 28943114

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters